<DOC>
	<DOC>NCT00828191</DOC>
	<brief_summary>Prospective, open, randomized, parallel, multicenter, two-arm trial to evaluate the efficacy and tolerability of a new progesterone formulation to be used for luteal support in IVF (Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg versus Progesterone tablets administered intravaginally at 100 mg twice daily for a total dose of 200 mg.</brief_summary>
	<brief_title>Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)</brief_title>
	<detailed_description />
	<mesh_term>Progesterone</mesh_term>
	<criteria>Patient has given written informed consent; BMI &lt; 30 kg/m2; Age 18 42 (upon starting COH); &lt;3 prior ART cycles (IVF, ICSI and related procedures); Baseline (day 23 of cycling) FSH &lt;15 IU/L and E2 &lt;80 pg/mL; Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyps or protruding submucosal fibroids); Patients must have at least three retrieved oocytes. Intramural uterine fibroids that distort the uterine cavity or polyps &gt;1 cm; Stage III or IV endometriosis (no endometriomas); Hydrosalpinges; History of past poor response to COH resulting in canceling ART; Use of thawed/donated oocytes; Use of thawed/donated embryos; Gestational carrier; Patients affected by pathologies associated with any contraindication of being pregnant; Hypersensitivity to study medication; Uncontrolled adrenal or thyroid dysfunction; History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product; History of arterial disease; Patients with hepatic impairment (liver function tests &gt; 2x upper limits of normal); Patients with dermatologic disease; Patients with renal impairment (estimated creatinine clearance &lt;60 mL/min/1.73 m2); Neoplasias (current) or history of neoplasia that may be responsive to progesterone; High grade cervical dysplasia; History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages, wherein pregnancy developed to a minimum of a gestational sac on TVUS; Participation in a concurrent clinical trial or in another trial within the past 2 months; Use of concomitant medications that might interfere with the study evaluation; Preimplantation genetic diagnosis/screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Luteal support in IVF</keyword>
</DOC>